摘要
A major problem in current cancer drug treatment is that a subset of cancer cells in many cases survives even highly efficient chemotherapy,and after a while,these remaining cells cause a recurrence of the disease.Moreover,the re-emerging cancer cells often show a multidrug-resistant phenotype,higher proliferation rate,higher invasiveness,and increased metastatic potential,as compared to original cancer.Cancer relapse and multidrug resistance are widely observed also in the most up-to-date,specifically targeted drug-or immunotherapies,causing an unsurmountable clinical inefficiency in cancer eradication.
